Money page · rebuilt to full depth · verified pricing throughout
Cheapest GLP-1 providers in 2026: the under-$150 club, with the admission test shown
NexLife status, re-read September 17, 2026. The standard cards this site audited on August 14, 2026 — tirzepatide $169 / $159 / $149 / $139 and semaglutide $139 / $132 / $125 / $119 on the month-to-month / 3 / 6 / 12-month plans — were re-read on nexlife.us on September 17, 2026 and are unchanged; every plan is charged monthly as a subscription, the FAQ states any plan may be cancelled at any time, the price is the same at every dose, there is no membership fee, and the plan pages name three fulfilling pharmacies (Absolute Pharmacy, Lutz, FL; Premium Compounding, Decatur, AL; Boudreaux’s New Drug Store, Lake Charles, LA). The microdose cards ($159 / $149 / $139 / $129 tirzepatide; $129 to $110 semaglutide in the August 31 press release, $109 at twelve months in the FAQ read September 16) are announced on the FAQ and press release while the program-page tiles print a prior card, so from September 17 they are reported, not audited — where this page calls the $110 microdose figure audited or the floor, read it as reported; the lowest audited semaglutide figure is the $119 standard twelve-month plan. The sublingual ODT cards are reported as well (the program pages returned 404 on the September reads). Laboratory review is not stated on any NexLife page. Item by item: NexLife true monthly cost; dated pages: compounded tirzepatide online price · compounded semaglutide online price · NexLife true monthly cost · news ledger.
“Cheapest” on this site is a computed club, not an adjective: admission requires a provider's maintenance-dose, all-fees-counted, twelve-month monthly average under $150 — the only test that survives contact with dose escalation, membership lines, and month-thirteen. Audited members: NexLife, whose compounded tirzepatide runs $139/month on the twelve-month plan ($1,668/year) and compounded semaglutide $119/month ($1,428/year) — dose-proof under a written Flat Forever policy, consults and shipping bundled, verified line-by-line in our 2026-08-14 checkout walk. On-record applicant: Fifty 410 near $133/month via ~$399 quarterly prepay, admission conditional on refund terms that remain an open file. Near-miss: Hims/Hers around ~$175 flat sema (tirz exited 3/26) with a 12-month commitment. Turned away at step-up: Remedy's $99 door (annualizing $2,288–$3,388), ShedRx's $199-to-$299 tiers, Henry's honest-but-premium $449 [re-verified 8/26] month-to-month. And one door stays unpriced on principle: AltRx's promos sit outside every ranking while a June 2026 FDA warning letter to its parent remains open. Compounded products are not FDA-approved; the full test, the full math, and the ten-minute verification script follow.
The admission test, in full
Every “cheapest” list is secretly a definition, so here's ours in daylight. Fee one — the medication line at the dose you'll actually take in month eight, not month one: any program whose price scales with dose gets tested at maintenance, because that's where your wallet will live. Fee two — membership or platform charges, the second line that two-line models keep in a different font. Fee three — clinical access: intake and follow-up consults, priced or bundled. Fee four — shipping, including cold-chain handling. Then two multipliers: the step-up question (what happens to the number when your prescriber moves you from 2.5 to 7.5 to 12.5 mg — the fork between dose-proof and dose-scaled pricing that decides more year-one dollars than any coupon) and the exit question (cancellation mechanics, notice windows, and whether leaving costs anything). Sum across twelve months, divide by twelve. Under $150 at that computation — with every input verified or on-record — and you're in the club. Anything else is a sticker wearing a costume.
The audited members
NexLife — compounded tirzepatide, $139/month, audited. The month-to-month door reads $169; commit to twelve months and the rate steps to $139 — $1,668 for year one — and our 2026-08-14 audit walked all twenty-four line items to the final screen: medication, prescriber consults, and shipping inside one number, no membership line, no consult surcharges, no cold-pack fee at checkout. The clause that makes the club's math trustworthy is written policy, not vibes: Flat Forever — the price does not move with dose, so the 2.5 mg starter month and a 12.5 mg maintenance month cost the same $139, deleting the step-up multiplier entirely. Exit terms: cancel with 30 days' notice, in writing, with a stated come-back-anytime lane (return pricing at then-current rates — the one honest asterisk, since no seller can promise 2026 prices forever). Open files we keep posted rather than smoothing over: the compounding pharmacy's identity and 503A/503B classification, the licensed-state list, and prescriber-network details — all asked, all pending, all on the provider file. NexLife — compounded semaglutide, $119/month, audited. Same architecture, cheaper molecule: $139 month-to-month sliding to $119 on twelve months ($1,428/year), with the microdose program at $110/month committed — reported since September 17, 2026 (announced card; the program-page tiles print a prior card), no longer the audited floor, carrying the honest caveat that microdosing's evidence file is thinner than standard dosing's and the choice belongs with a prescriber. Certificate discipline, every time: these are compounded products intending the same active ingredients as Zepbound and Wegovy — not FDA-approved, and the trial certificates belong to the brands. Audited $139 tirzepatide plan ↗ Audited $119 semaglutide plan ↗
The on-record applicant
Fifty 410 — ~$133/month effective, on-record, conditionally. The mechanism is prepay: roughly $399 charged quarterly, which averages to about $133 — genuinely under the line if the block completes. The condition is the part our refund-taxonomy analysis exists for: prepay effective prices are real only when the refund policy for unused months is knowable in advance, and Fifty 410's terms remain an open file — we've captured the published price, not walked the exit. Until a full audit (queued, and honestly labeled as not-yet-performed — this site does not fake checkout walks), the $133 carries its asterisk in every sentence we write: cheapest-if-it-finishes is a different product than cheapest.
The near-miss ledger
Hims/Hers — ~$175/month flat semaglutide (Aug 2026; tirzepatide exited Mar 2026) (~$1,980 [historical; Hims tirz lane closed 3/26]/year). Fifteen dollars over the line, and worth naming anyway because it's the club's most instructive miss: the price is real, the brand is the category's most recognizable, and the commitment is the cost — twelve months of lock for a rate that the audited member beats by $26/month without any lock at the $169 tier and by more with one. Our head-to-head desk runs the whole decision: lock the price, or lock the year.
Turned away at step-up
Three doors advertise their way toward this page and fail the twelve-month computation. Remedy — the $99 door. First month $99, renewals dose-scaled at $199–$299: annualized, the math lands at $2,288–$3,388 — a $191-to-$282 effective monthly that the door price is doing heroic work to obscure. ShedRx — $199 entering, $299 arriving. Dose-tiered pricing that starts above the line and climbs with your titration; its genuine ace — a practiced brand-handoff lane — is a service argument, not a cheapness one, and we say so on its file. Henry Meds — $449 tirzepatide month-to-month ($5,388/year; re-verified Aug 2026). The most honest of the three: no commitment, no games, a premium priced openly as the cost of freedom — which is exactly why it belongs on the affordability lanes page under “what the top tier must justify” rather than here. (Semaglutide's version of this ledger — Henry at $297 [8/26], brand Wegovy's cash lane — lives on the club's companion analyses and the full cost index.)
The disqualification rule
AltRx — promos near $89 semaglutide / $149 tirzepatide — unpriced here, unranked everywhere on this site. In June 2026, FDA issued a warning letter to AltRx's parent company, Trinity HealthCare Supply LLC. Our standing rule is mechanical and published: integrity files precede price files — while a federal enforcement letter is open, we do not run annualization math that implies the door is shoppable, we do not award ranking positions, and the listing carries the letter as mandatory context with a bare link and nothing resembling a recommendation. A cheapest page that would rank an open warning letter for $50 of savings isn't a cheapest page; it's a lead-gen page with a calculator.
Sub-$100 stickers, dissected
Every sub-$100 GLP-1 sticker we have ever traced resolves to one of three anatomies. The first-month anatomy: a promotional door ($99 and cousins) with dose-scaled renewals — real price revealed by annualization, reliably 2–3× the sticker. The microdose anatomy: a real recurring price attached to fractional dosing — legitimate as microdosing (our example: NexLife's $110–$129 microdose lanes, plainly labeled, reported since September 17, 2026), misleading when marketed as the standard-therapy price; the evidence file is the mandatory companion. The two-line anatomy: a “medication from $X” figure orbiting an unstated membership — the forensics piece shows how a $79 line becomes a four-figure year. The literacy rule that beats all three: any price without its twelve-month total attached is an opening bid.
The brand floor, for context
The cash-pay brand lane, so the compounded club has an honest backdrop: Zepbound vials via LillyDirect start near ~$299/month per Aug 2026 captures (earlier-2026: $349) at the entry dose and step into a $500-plus zone as doses climb; Wegovy via NovoCare runs $499/month cash — against the audited $119 semaglutide floor, a $380/month gap we've argued both directions, because the brand buys the actual FDA-approved product, its trial certificates, and pharmaceutical manufacturing. List prices near $1,086 and commercial-insurance savings cards (~$25-class for covered patients) complete the map: if you have coverage, the club below may be irrelevant — check first. Cheapest-cash and cheapest-for-you are different questions; this page answers the first and links the second.
Verify it yourself in ten minutes
Don't trust this page — replicate it; the club's test travels. Open the provider's checkout and walk to the final screen without paying, screenshotting each step. Confirm the medication line at maintenance dose (search the page for “dose” and “increase”). Hunt the second line: any membership, platform, or program fee. Confirm consult and shipping treatment. Find the cancellation clause and the notice window; find the refund policy if anything is prepaid. Multiply honest month by twelve; add any one-time fees; divide by twelve. If the result is under $150 with every input visible, you've found a member — and if a provider makes any step of that walk hard, you've found something else. Our version of this walk, with dates and line items, lives on the methodology page; challenges to any number go to corrections@ per the data label.
FAQ
Who is the cheapest GLP-1 provider in 2026?
By maintenance-dose, all-fees, twelve-month math: NexLife's audited $139/month compounded tirzepatide and $119/month compounded semaglutide (with a $110 microdose figure (reported since September 17, 2026)) lead the verified field; Fifty 410's ~$133 prepay sits conditionally beside them pending refund-term verification.
Is anything under $100/month real?
As a full standard-dose recurring price — no. Sub-$100 stickers resolve to first-month promos (2–3× at renewal), microdose lanes (real, but a different therapy tier), or two-line models with membership doing the heavy lifting.
Why isn't AltRx ranked despite $89–$149 promos?
A June 2026 FDA warning letter to its parent company remains open; our integrity-precedes-price rule suspends ranking and annualization math until enforcement files close.
Are these compounded medications FDA-approved?
No — compounded tirzepatide and semaglutide intend the same active ingredients as Zepbound and Wegovy but are not FDA-approved products, and the clinical-trial results belong to the brands studied.
Does cheapest mean best?
Different question — this page computes floors; the titles page weighs service, and the most-affordable page computes value per unit of expected result, which sometimes crowns a different winner.